Bio-Techne Statistics
Total Valuation
Bio-Techne has a market cap or net worth of $12.51 billion. The enterprise value is $12.86 billion.
| Market Cap | 12.51B |
| Enterprise Value | 12.86B |
Important Dates
The last earnings date was Wednesday, May 1, 2024, before market open.
| Earnings Date | May 1, 2024 |
| Ex-Dividend Date | May 10, 2024 |
Share Statistics
Bio-Techne has 157.59 million shares outstanding. The number of shares has decreased by -0.69% in one year.
| Shares Outstanding | 157.59M |
| Shares Change (YoY) | -0.69% |
| Shares Change (QoQ) | +0.27% |
| Owned by Insiders (%) | 0.97% |
| Owned by Institutions (%) | 102.08% |
| Float | 155.83M |
Valuation Ratios
The trailing PE ratio is 63.51 and the forward PE ratio is 40.09. Bio-Techne's PEG ratio is 1.15.
| PE Ratio | 63.51 |
| Forward PE | 40.09 |
| PS Ratio | 10.84 |
| Forward PS | 10.09 |
| PB Ratio | 6.21 |
| P/FCF Ratio | 49.81 |
| PEG Ratio | 1.15 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 36.31, with an EV/FCF ratio of 51.20.
| EV / Earnings | 63.35 |
| EV / Sales | 11.14 |
| EV / EBITDA | 36.31 |
| EV / EBIT | 52.80 |
| EV / FCF | 51.20 |
Financial Position
The company has a current ratio of 4.08, with a Debt / Equity ratio of 0.25.
| Current Ratio | 4.08 |
| Quick Ratio | 2.49 |
| Debt / Equity | 0.25 |
| Debt / EBITDA | 1.40 |
| Debt / FCF | 1.97 |
| Interest Coverage | 21.72 |
Financial Efficiency
Return on equity (ROE) is 10.20% and return on invested capital (ROIC) is 8.89%.
| Return on Equity (ROE) | 10.20% |
| Return on Assets (ROA) | 7.50% |
| Return on Capital (ROIC) | 8.89% |
| Revenue Per Employee | $378,453 |
| Profits Per Employee | $66,558 |
| Employee Count | 3,050 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 2.20 |
Taxes
In the past 12 months, Bio-Techne has paid $29.34 million in taxes.
| Income Tax | 29.34M |
| Effective Tax Rate | 12.63% |
Stock Price Statistics
The stock price has decreased by -4.56% in the last 52 weeks. The beta is 1.23, so Bio-Techne's price volatility has been higher than the market average.
| Beta (1Y) | 1.23 |
| 52-Week Price Change | -4.56% |
| 50-Day Moving Average | 72.08 |
| 200-Day Moving Average | 70.61 |
| Relative Strength Index (RSI) | 56.39 |
| Average Volume (30 Days) | 1,124,614 |
Short Selling Information
The latest short interest is 6.72 million, so 4.27% of the outstanding shares have been sold short.
| Short Interest | 6.72M |
| Short Previous Month | 5.93M |
| Short % of Shares Out | 4.27% |
| Short % of Float | 4.31% |
| Short Ratio (days to cover) | 5.36 |
Income Statement
In the last 12 months, Bio-Techne had revenue of $1.15 billion and earned $203.00 million in profits. Earnings per share was $1.25.
| Revenue | 1.15B |
| Gross Profit | 771.08M |
| Operating Income | 255.39M |
| Pretax Income | 232.35M |
| Net Income | 203.00M |
| EBITDA | 354.14M |
| EBIT | 243.56M |
| Earnings Per Share (EPS) | $1.25 |
Balance Sheet
The company has $145.31 million in cash and $494.73 million in debt, giving a net cash position of -$349.42 million or -$2.22 per share.
| Cash & Cash Equivalents | 145.31M |
| Total Debt | 494.73M |
| Net Cash | -349.42M |
| Net Cash Per Share | -$2.22 |
| Equity / Book Value | 2.01B |
| Book Value Per Share | 12.78 |
| Working Capital | 460.83M |
Cash Flow
In the last 12 months, operating cash flow was $306.88 million and capital expenditures -$55.73 million, giving a free cash flow of $251.15 million.
| Operating Cash Flow | 306.88M |
| Capital Expenditures | -55.73M |
| Free Cash Flow | 251.15M |
| FCF Per Share | $1.60 |
Margins
Gross margin is 66.80%, with operating and profit margins of 22.13% and 17.59%.
| Gross Margin | 66.80% |
| Operating Margin | 22.13% |
| Pretax Margin | 20.13% |
| Profit Margin | 17.59% |
| EBITDA Margin | 30.68% |
| EBIT Margin | 21.10% |
| FCF Margin | 21.76% |
Dividends & Yields
This stock pays an annual dividend of $0.32, which amounts to a dividend yield of 0.40%.
| Dividend Per Share | $0.32 |
| Dividend Yield | 0.40% |
| Dividend Growth (YoY) | -50.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 25.60% |
| Buyback Yield | 0.69% |
| Shareholder Yield | 1.10% |
| Earnings Yield | 1.62% |
| FCF Yield | 2.01% |
Analyst Forecast
The average price target for Bio-Techne is $81.11, which is 2.17% higher than the current price. The consensus rating is "Buy".
| Price Target | $81.11 |
| Price Target Difference | 2.17% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | 7.96% |
| EPS Growth Forecast (5Y) | 12.72% |
Stock Splits
The last stock split was on November 30, 2022. It was a forward split with a ratio of 4:1.
| Last Split Date | Nov 30, 2022 |
| Split Type | Forward |
| Split Ratio | 4:1 |
Scores
Bio-Techne has an Altman Z-Score of 12.21 and a Piotroski F-Score of 6.
| Altman Z-Score | 12.21 |
| Piotroski F-Score | 6 |